1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Childhood-Onset Fluency Disorder: new trials by email Literature Review of Childhood-Onset Fluency Disorder trials Research Report on Childhood-Onset Fluency Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Ecopipam 50mg, Ecopipam 100mg - Stuttering, Adult, Childhood-onset Fluency Disorder | Phase 2 / Phase 3 | Unknown | Gerald Maguire, MD | 10 | 2016-09-01 | 2016-10-26 |
Communication Disorders (1) · Language Disorders (1) · Speech Disorders (1) · Stuttering (1)
Mental Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurodevelopmental Disorders (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
ecopipam (1)
United States (1)
PMID 10917410, PMID 12849360, PMID 15026214, PMID 15212606, PMID 15328899, PMID 20075648, PMID 24434529